ROBERT BAFFI - 18 Dec 2023 Form 3 Insider Report for Neurogene Inc. (NGNE)

Role
Director
Signature
/s/ Christine Mikail, as attorney-in-fact for Robert Baffi
Issuer symbol
NGNE
Transactions as of
18 Dec 2023
Net transactions value
$0
Form type
3
Filing time
26 Dec 2023, 18:10:12 UTC
Previous filing
22 Feb 2022
Next filing
18 Jan 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding NGNE Stock Option (Right to Buy) 18 Dec 2023 Common Stock 3,402 $10.71 Direct F1
holding NGNE Stock Option (Right to Buy) 18 Dec 2023 Common Stock 5,670 $23.02 Direct F2
holding NGNE Stock Option (Right to Buy) 18 Dec 2023 Common Stock 2,570 $18.39 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option represents a right to purchase 3,402 shares of the Issuer's common stock and is fully vested.
F2 This option represents a right to purchase 5,670 shares of the Issuer's common stock and is fully vested.
F3 This option represents a right to purchase 2,570 shares of the Issuer's common stock. 50% of this option will vest on March 9, 2024, with the remainder vesting on March 9, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Remarks:

Exhibit 24 - Power of Attorney